Orbimed Advisors LLC Prelude Therapeutics Inc Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
A detailed history of Orbimed Advisors LLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 10,909,256 shares of PRLD stock, worth $15.8 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
10,909,256
Previous 10,909,256
-0.0%
Holding current value
$15.8 Million
Previous $8.4 Million
5.19%
% of portfolio
0.32%
Previous 0.26%
Shares
3 transactions
Others Institutions Holding PRLD
# of Institutions
50Shares Held
27.9MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY10.1MShares$14.7 Million0.08% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.55 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA933KShares$1.35 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD928KShares$1.35 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny582KShares$843,6100.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $52.7M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...